Access Only Access1 Access2 Access3 Drugs News July 5, 2024 Press Release – Roche’s Tecentriq® SC (atezolizumab) becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Singapore, reducing treatment time to a few minutes
Access1 Access2 Medication & Drugs March 24, 2022 Singapore’s HSA New Drugs and Indications Approval – Feb 2022
Access1 Access2 Medication & Drugs February 24, 2022 Singapore’s HSA New Drugs and Indications Approval – Jan 2022
Access1 Access2 Medication & Drugs January 25, 2022 Singapore’s HSA New Drugs and Indications Approval – Dec 2021
Access1 Access2 Medication & Drugs December 30, 2021 Singapore’s HSA New Drugs and Indications Approval – Nov 2021
Access1 Access2 Medication & Drugs December 3, 2021 Singapore’s HSA New Drugs and Indications Approval – Oct 2021
Access1 Access2 Medication & Drugs October 26, 2021 Singapore’s HSA New Drugs and Indications Approval – Sep 2021
